15/12/2025 - Research

Occupational factors strongly influence Long-COVID risk

Work-related factors play a significant and independent role in the risk of developing Long-COVID, shows a new study based on the COVICAT cohort and led by ISGlobal, in collaboration with the University of Turin and the IGTP. The findings, published in BMJ Occupational & Environmental Medicine, highlight that a substantial share of Long-COVID could be prevented through targeted workplace measures and policies.

02/12/2025 - Research

New evidence on the therapeutic potential of extracellular vesicles in kidney injury

Researchers at IGTP have published an article analysing the therapeutic potential of extracellular vesicles derived from mesenchymal stem cells to address kidney injury, reviewing current evidence on how these vesicles can interact with renal tubular epithelial cells.

27/11/2025 - Campus Can Ruti, Research

New study maps the landscape of KRAS mutations and targeted therapies in colorectal cancer

A team of researchers from IGTP and ICO has studied alterations in the KRAS gene in colorectal cancer by combining genomic analyses with a systematic review of targeted compounds and clinical trials. Their findings, published in the journal npj Precision Oncology, provide and updated overview to guide future advances in this cancer's treatment.

21/11/2025 - Research

A new cellular model reveals which mutations drive progression to myelodysplastic syndrome and leukemia in patients with GATA2 deficiency

A research team has created the first humanised cellular model to study GATA2 deficiency, a rare genetic disorder that predisposes individuals to severe blood conditions such as myelodysplastic syndrome and leukaemia. The study shows that, although the initial GATA2 mutation weakens haematopoietic stem cells, it is additional mutations -particularly in the SETBP1 gene- that drive disease progression. 

17/11/2025 - Projects, Research

Micropores pave the way for infection research

A new study provides a powerful way to study infections in environments that closely mimic human organs. The strategy, tested in a bone-marrow-on-chip model, was developed by researchers from ISGlobal, IGTP, I3S at Porto University, and IN2UB, as part of the HIDDENVIVAX project, funded by "la Caixa" Foundation.

04/11/2025 - Research

Study identifies that the sequence of previous diseases may help predict the risk of long COVID

Provides a new perspective: what matters is not only which previous diseases a person has, but also the order in which they appeared and how they interact. This approach makes it possible to identify risk profiles for long COVID that had not been detected until now. The research was conducted within the framework of the COVICAT study, coordinated in collaboration with ISGlobal.

30/10/2025 - Campus Can Ruti, Projects, Research

Precision increases in a project led by Germans Trias using AI to detect early facial changes in patients with acromegaly

A project led by the Germans Trias i Pujol University Hospital and Research Institute has developed an AI-based facial recognition system, AcroFace, capable of detecting early signs of acromegaly with 93% accuracy. The researchers are now conducting a larger pilot study with 4,000 images from the general population to confirm these promising results and improve early diagnosis of this rare disease.

22/10/2025 - Campus Can Ruti, Research

Tears could open a new avenue for diagnosing and monitoring eye and neurodegenerative diseases

Researchers from the IGTP and HUGTiP have reviewed the current knowledge on the use of tear-derived extracellular vesicles as a source of biomarkers for both ocular and neurodegenerative diseases. They highlight the advantages of this approach compared with more invasive methods and discuss the remaining challenges for its clinical application.

16/10/2025 - Innovation, Research, Success Stories

HIPRA receives European Commission approval for the commercialisation of its COVID-19 vaccine adapted to the LP.8.1 variant

The demonstration of the vaccine's efficacy in its preclinical phase was carried out at the Comparative Medicine and Bioimage Centre of Catalonia, a trategic project of IGTP.

14/10/2025 - Campus Can Ruti, Research

RUTI® vaccine improves treatment of non-invasive bladder cancer by boosting immune response and providing clinical benefits

A clinical trial involving 40 patients, led by IrsiCaixa and IGTP and conducted at HUGTiP, confirms that the RUTI® vaccine, owned by Archivel Farma, enhances the effectiveness of the current treatment for non-muscle-invasive bladder cancer.